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Abstract
Background: Studies investigating the genetic and environmental characteristics of atrial fibrillation (AF) may
provide new insights in the complex development of AF. We aimed to investigate the association between several
environmental factors and loci of candidate genes, which might be related to the presence of AF.
Methods:  A nested case-control study within the PREVEND cohort was conducted. Standard 12 lead
electrocardiograms were recorded and AF was defined according to Minnesota codes. For every case, an age and
gender matched control was selected from the same population (n = 194). In addition to logistic regression
analyses, the multifactor-dimensionality reduction (MDR) method and interaction entropy graphs were used for
the evaluation of gene-gene and gene-environment interactions. Polymorphisms in genes from the Renin-
angiotensin, Bradykinin and CETP systems were included.
Results: Subjects with AF had a higher prevalence of electrocardiographic left ventricular hypertrophy, ischemic
heart disease, hypertension, renal dysfunction, elevated levels of C-reactive protein (CRP) and increased urinary
albumin excretion as compared to controls. The polymorphisms of the Renin-angiotensin system and Bradykinin
gene did not show a significant association with AF (p > 0.05). The TaqIB polymorphism of the CETP gene was
significantly associated with the presence of AF (p < 0.05). Using the MDR method, the best genotype-phenotype
models included the combination of micro- or macroalbuminuria and CETP TaqIB polymorphism, CRP >3 mg/L
and CETP TaqIB polymorphism, renal dysfunction and the CETP TaqIB polymorphism, and ischemic heart disease
and CETP TaqIB polymorphism (1000 fold permutation testing, P < 0.05). Interaction entropy graph showed that
the combination of albuminuria and CETP TaqIB polymorphism removed the most entropy.
Conclusion: CETP TaqIB polymorphism is significantly associated with the presence of AF in the context of
micro- or macroalbuminuria, elevated C-reactive protein, renal dysfunction, and ischemic heart disease.
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Background
Atrial fibrillation (AF) is the most common sustained
arrhythmia in clinical practice and is associated with an
increase in total and cardiovascular mortality, as well as
cardiovascular morbidity, including stroke and heart fail-
ure. [1]. It is therefore important to detect and treat AF at
an early stage to prevent refractory AF and cardiovascular
events in the future. Currently, our knowledge on the early
pathophysiological changes in the atria is limited due to
lacking understanding of molecular mechanisms. Studies
in genetics of AF may provide some new insights in the eti-
ology of AF. The familial form of AF is uncommon and AF
is more often related to structural abnormalities. There-
fore, analysis of AF as monogenic disease in family mem-
bers with AF as primary electrical disease will tell us more
about the etiology of AF, but cohort studies comparing
cases to age and gender matched controls may explain the
development of AF and identify genetic factors that pre-
dispose subjects to AF in combination with structural
abnormalities [2]. Recently, activation of the renin-angi-
otensin system (RAS) and higher inflammatory state has
been associated with AF in the future. [3,4]. Activation of
RAS may cause the development of structural abnormali-
ties partly by degrading bradykinin, which normally has a
cardioprotective effect by diminishing the development of
fibrosis. [5]. It was already known from studies in experi-
mental AF that inhibition of the RAS prevents adverse
atrial remodeling. [6]. Furthermore, genetic variations in
the renin angiotensin system genes and inflammatory
genes are associated with AF indicating the complexity of
the development of AF [7,8]. Genetic variations in the
cholesteryl ester transfer protein (CETP) gene are also
interesting candidates to play an important role in cardio-
vascular disease. CETP enables the transfer of cholesteryl
esters from high density lipoprotein (HDL) towards lipo-
proteins of lower density, thereby lowering HDL choles-
terol. [9]. A high CETP concentration may be a
determinant of increased cardiovascular risk in subjects
with high triglycerides [10]. Variations in the CETP gene
could be involved in the development of cardiovascular
disease by increasing CETP activity and thereby reducing
the cholesterol content of HDL relative to low density
lipoprotein (LDL). Furthermore, a decreased CETP activ-
ity might prevent oxidation of LDL and decrease inflam-
mation of the vascular wall through its effect on HDL
[11]. Accumulating evidence suggests that CETP polymor-
phisms may be linked to coronary artery disease, as well
as hypertension, which are both strongly linked to the
incidence of AF. [12,13].
It is increasingly clear that the relationship between the
genome and susceptibility to cardiovascular disease is
complex [14]. As such, genetic analysis methods are
needed that embrace, rather than ignore, this complexity
[15]. In this case-control study, we investigate the associa-
tion between several environmental factors and loci of
candidate genes, which might be related to the presence of
AF. In addition to the traditional univariate analyses, we
explored the effects of gene-gene and gene-environment
interactions on AF using the multifactor dimensionality
reduction (MDR) method and creating an interaction
entropy graph [16].
Methods
Subjects
The population analyzed in this study was obtained from
the PREVEND study. [17]. The PREVEND (Prevention of
Renal and Vascular Endstage Disease) study was designed
to investigate the natural course of microalbuminuria and
its relation with renal and cardiovascular disease in the
general population. [17]. All inhabitants of the city of
Groningen (Netherlands) between age 28–75 were asked
to send in a morning urine sample and to fill in a short
questionnaire on demographics and cardiovascular medi-
cal history. A total of 40,856 subjects responded. Subjects
who were pregnant or using insulin were excluded. All
subjects with a urinary albumin concentration ≥ 10 mg l-1
(n = 7,768) and a randomly selected sample of subjects
with a urinary albumin concentration <10 mg l-1 (n =
3,395) were invited to perform two visits at an outpatient
clinic. The screening program was completed by 8,592
subjects. From these, we selected all patients with AF on
the electrocardiogram (n = 97). For every case, an age and
gender matched control was selected from the PREVEND
cohort. All participants gave written informed consent.
The PREVEND study was approved by the local medical
ethics committee and conducted in accordance with the
guidelines of the declaration of Helsinki.
Electrocardiography
Standard 12-lead electrocardiograms were recorded using
the computer program MEANS (Modular ECG Analysis
System) [18], and AF was defined according to Minnesota
codes 8.3.1 and 8.3.3. Infarct patterns, suggestive of myo-
cardial infarction, were defined by Minnesota codes 1.1
and 1.2. Major ischemia was defined by Minnesota codes
4.1, 4.2, 5.1, or 5.2. The presence of left ventricular hyper-
trophy (LVH) was identified using the Cornell voltage-
duration product, which was calculated as follows: RaVL
± SV3 (with 6 mm added in women) × QRS duration. A
threshold of 2440 mm·msec was used to identify LVH.
Laboratory measurements
The urinary albumin excretion rate was measured as the
mean of two 24-h urine collections, and microalbuminu-
ria was defined as an albumin excretion rate between 30
and 300 mg per 24 h and macroalbuminuria > 300 mg per
24 h. Urinary albumin concentrations were determined
by nephelometry with a threshold of 2.3 mg l-1 and intra-
and inter-assay coefficients of variation of less than 2.2%BMC Medical Genetics 2006, 7:39 http://www.biomedcentral.com/1471-2350/7/39
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and 2.6%, respectively (Dade Behring Diagnostic, Mar-
burg, Germany). High-sensitive C-reactive protein (CRP)
was also determined by nephelometry with a threshold of
0.175 mg l-1 and intra- and inter-assay coefficients of less
than 4.4% and 5.7%, respectively (BNII N, Dade
Behring). CRP levels below the detection level were scored
as 0.18 mg l-1. Plasma glucose, serum cholesterol, serum
and urinary creatinine were determined by Kodak
Ektachem dry chemistry (Eastman Kodak, Rochester, NY,
USA). HDL-cholesterol was measured with a homogene-
ous method (direct HDL, no. 7D67, AEROSET System;
Abbott Laboratories). Serum triglycerides were measured
enzymatically. [9]. LDL-cholesterol is estimated from
quantitative measurements of total and HDL-cholesterol
and triglycerides using the empirical relationship of
Friedewald et al. [19]. Urinary leukocyte and erythrocyte
measurements were done by Nephur-test+leuco sticks
(Boehringer Mannheim, Mannheim, Germany).
Genotyping of the RAS, Bradykinin and CETP gene 
polymorphisms
The AGT A-6G (rs5051) single nucleotide polymorphisms
was analyzed using PCR primers and dual labeled Taq-
Man (non-MGB) probes as described earlier. [20]. The
AT1R A-1166C (rs5186), the BDKRB2 C-58T (rs1799722)
and C-181T (rs1046248), and the CETP Taq1B
(rs708272) and I-405V (rs5882) polymorphisms were
analyzed using TaqMan-MGB probes and PCR primers,
designed through the Assay-by-Design service (Applied
Biosystems). The ACE I/D and the BDKRB2 exon 1 inser-
tion/deletion polymorphisms were also analyzed by PCR
amplification, one of the primers having a fluoresent
label, and subsequent determination of the lengths of the
PCR products on a capillary sequencer. Primers were
picked with the aid of online Primer3 software [21]. After
PCR cycling, samples of the above assays were pooled and
separated on a MegaBACE 1000 sequencer. Fragments
were analyzed with Genetic Profiler 2.0 software (Amer-
sham Biosciences).
Definition of risk factors
Hypertension was defined as a systolic blood pressure ≥
140 mm Hg or a diastolic blood pressure ≥ 90 mm Hg or
the use of antihypertensive medication. Hypercholestero-
lemia was defined as a total serum cholesterol level of ≥
6.5 mmol/l or the use of lipid-lowering therapy. Diabetes
was defined as a fasting plasma glucose level >7.0 mmol/
l or a non-fasting plasma glucose level >11.1 mmol/l or
the use of antidiabetic medication. Obesity was defined as
a body mass index ≥ 30 kg/m2. Smoking was categorized
as no smoking or current smoking (current or stopped <1
year ago). Creatinine clearance (CrCl) was calculated as
the mean of two 24-h urine creatinine excretions divided
by plasma creatinine. Creatinine clearance was adjusted
for body surface area, BSA = 0.007184 × weight0.425 ×
length0.725, by dividing CrCl by BSA. Moderate renal dys-
function was defined as CrCl <60 mL/min/1.73 m2 or the
presence of microalbuminuria. Presence of ischemic heart
disease was defined as prior myocardial infarction with
hospitalization reported by questionnaire and/or an inf-
arct and/or major ischemia patterns on the electrocardio-
gram.
Statistical analysis
Continuous data are reported as mean (standard devia-
tion) or median (interquartile range) if the data was
skewed. Categorical data are presented as per group per-
centages. Differences between subgroups were evaluated
by Student's t-test for the normally distributed continuous
variables, or by the Mann-Whitney test if data was skewed.
Differences in genotype frequencies and other categorical
data between cases and controls were compared with the
χ2 test or Fisher's exact test. Consistency of genotype fre-
quencies with the Hardy-Weinberg equilibrium (HWE)
was tested using a chi-squared goodness-of-fit test on a
contingency table of observed versus expected genotype
frequencies in cases and controls. The expected genotype
frequencies were calculated using allele frequencies esti-
mated from the control sample of the entire PREVEND
cohort. When departure of HWE was detected in the con-
trol group, the Armitage test for trend in proportions was
used which does not assume HWE [22]. Genotype-pheno-
type associations were examined with dominant, and
recessive models using logistic regression. Odds ratios for
the presence of AF on the electrocardiogram and their
95% Confidence intervals were calculated. All p-values are
two-tailed. A p-value of <0.05 was considered statistically
significant. All abovementioned calculations were per-
formed with SPSS version 12.0.1 software (SPSS, Chicago,
IL).
For the evaluation of gene-gene and gene-environment
interactions, we used the MDR method [23-26]. This
method includes a combined cross-validation/permuta-
tion-testing procedure that minimizes false-positive
results that might otherwise result from multiple exami-
nations of the data [27]. Cross-validation divides the data
into a training set and a testing set. With 10-fold cross-val-
idation, the data are divided into 10 equal parts, and the
model is developed on 9/10 of the data (training set) and
then tested on 1/10 of the remaining data (testing set).
This is repeated for each possible 9/10 and 1/10 of the
data, and the resulting 10 testing accuracies are averaged.
In addition to the testing accuracy, we also report the
cross-validation consistency (CVC) that is a measure of
how many times out of 10 divisions of the data that MDR
found the same best model. Models that are true-positives
are likely to generalize to independent datasets and will
have estimated testing accuracies of greater than 0.5. Per-
mutation testing was performed to assess the probabilityBMC Medical Genetics 2006, 7:39 http://www.biomedcentral.com/1471-2350/7/39
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of obtaining a testing accuracy as large or larger than
observed in the original data given the null hypothesis of
no association is true. This is carried out by randomizing
the case-control labels 1000 times and repeating the MDR
analysis on each randomized dataset. This process yields
an empirical distribution of testing accuracies under the
null hypothesis that is in turn used to calculate a p-value.
We report here the significant two-factor models. The
MDR analysis was carried out using version 0.5.1 of the
open-source MDR software package that is freely availa-
ble. [28].
The following cardiovascular risk factors predisposing to
AF were included in the MDR analysis: hypertension,
hypercholesterolemia, obesity, diabetes, current smoking,
family history for cardiovascular disease, HDL-cholesterol
< 1 mmol/l, alcohol intake > = 1 drink per day, CRP > 3
mg/L, presence of micro- or macroalbuminuria, renal dys-
function, electrocardiographic left ventricular hypertro-
phy and ischemic heart disease.
The following genotypes were included in the MDR anal-
ysis: ACE gene insertion/deletion (I/D) polymorphism,
the -6GA polymorphism of the Angiotensin (AGT) gene,
the A1166C polymorphism of the angiotensin II type 1
receptor gene (AT1R), Bradykinin B2 receptor gene -81CT,
-58CT, 9bp insertion/deletion polymorphisms, and the
CETP TaqIB, I405V polymorphisms.
An interaction graph using entropy (measurement of ran-
domness) estimates as described by Jakulin and Bratko.
[29] and Moore et al [16] will be created to confirm, visu-
alize and interpret the results obtained by logistic regres-
sion analysis and MDR. Interaction graphs are
compromised of a node for each attribute with pairwise
connections between them. The percentage of entropy
removed by each attribute is visualized for each node and
the percentage of entropy removed for each pairwise
product of attributes is visualized for each connection.
Thus, the independent main effects of each factor can be
compared to the interaction effect and whether interac-
tions are additive or non-additive can be quickly deter-
mined. Positive entropy values indicate synergistic
interaction and negative entropy values indicate redun-
dancy. The interaction graphs are created using Orange
machine learning software package, which is written in
Python and provided for free as open-source [30].
Results
The clinical characteristics of cases and controls are shown
in Table 1. Subjects with AF had a higher prevalence of
electrocardiographic LVH, ischemic heart disease, hyper-
tension, renal dysfunction, and higher levels of CRP and
urinary albumin excretion as compared to age and gender
matched controls.
Table 1: Baseline characteristics of the nested case-control study divided by control group of subjects without atrial fibrillation (AF) 
and cases with AF. Data shown as percentages for categorical variables and mean ± standard deviation for continuous variables. HDL-
cholesterol, Triglycerides, Creatinine, C-reactive protein, and urinary albumin excretion are expressed as median [interquartile 
range].
AF Controls (n = 97) AF Cases (n = 97) P-value
Age, years 59 ± 1 60 ± 1 Matched
Male 56.7% 56.7% Matched
Caucasian 91.8% 92.8% 0.79
Body Mass Index 27.1 ± 0.4 27.8 ± 0.4 0.24
Current smoking 28.9% 30.2% 0.84
Ischemic heart disease 15.8 % 38.0 % 0.001
Left ventricular hypertrophy 3.1% 11.5% 0.03
Systolic blood pressure 135 ± 2 137 ± 2 0.47
Diastolic blood pressure 76 ± 1 79 ± 1 0.03
Hypertension 42.7% 60.6% 0.01
Diabetes Mellitus 5.2% 6.2% 0.77
HDL-cholesterol, mmol/l 1.24 [1.01–1.56] 1.18 [0.93–1.47] 0.29
Total cholesterol, mmol/l 5.9 ± 0.10 5.7 ± 0.11 0.14
LDL cholesterol, mmol/l 4.0 ± 1.0 3.8 ± 1.0 0.15
Triglycerides, mmol/l 1.2 [0.9–1.9] 1.3 [0.9–1.7] 0.49
Creatinine (µmol/L) 84 [75–95] 86 [78–105] 0.07
Creatinine clearance (mL/min/1.73 m2) 90.9 ± 25.7 81.2 ± 23.4 0.01
Moderate renal dysfunction 14.0% 40.2% <0.01
C-reactive protein (mg/L) 1.55 [0.66–2.81] 2.28 [1.18–4.81] <0.01
Urinary albumin excretion 11.95 [7.07–21.44] 17.75 [8.92–45.35] <0.01
Alcohol intake > = 1 drink per day 24.7 % 23.7 % 0.87BMC Medical Genetics 2006, 7:39 http://www.biomedcentral.com/1471-2350/7/39
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Except for the CETP I405V genotype (p = 0.03), all poly-
morphisms examined in this study were in HWE both in
the cases as in the controls. The frequencies of the geno-
types are listed in Table 2. In the same table, the results of
the association study using the dominant and recessive
models are given. The polymorphisms of the RAS and
Bradykinin gene did no show a significant association
with AF in this case-control study. The two genetic varia-
tions in the CETP gene were associated with AF. The I405V
genotype was associated with AF in the recessive model (p
= 0.015)and TaqIB in the dominant model (p = 0.005).
The Armitage test (not assuming HWE) for trend was used
to replicate the associations found using logistic regres-
sion. Using the Armitage test, CETP I405V was not signif-
icantly associated with AF (p for trend = 0.34). CETP
TaqIB polymorphism remained significant associated
with AF (p for trend = 0.03). After adjustment for other
significant risk factors predisposing to AF (presence of
electrocardiographic LVH, ischemic heart disease, hyper-
tension, renal dysfunction, elevated CRP, and micro- or
macroalbuminuria), the association between CETP TaqIB
polymorphism and AF remained significant (Odds ratio
[95% confidence intervals] for AF: 0.35 [0.16–0.76], p =
0.008).
Table 3 and Figure 1 shows the best interaction models to
explain AF in this study as determined by MDR analysis.
The overall best interaction model included the combina-
tion of micro- or macroalbuminuria and CETP TaqIB pol-
ymorphism. Other significant models were the
combination of CRP >3 mg/L and the CETP TaqIB poly-
morphism, the combination of renal dysfunction and the
CETP TaqIB polymorphism, and the combination of
ischemic heart disease and CETP TaqIB polymorphism (P
< 0.05). Similar significant interactions were found for the
CETP I405V polymorphism (data not shown because of
deviation HWE).
Table 2: Distribution of genotypes in controls without atrial fibrillation (AF) and subjects with AF.
Locus AF Controls (n = 97) AF Cases (n = 97) P value (Chi-square) OR (95%CI)*
ACE gene I/D 0.44
II 22.7% 31.1% 0.65 (0.33–1.27)
ID 50.0% 43.3% 0.92 (0.47–1.78)
DD 27.3% 25.6%
AGT gene G-6A 0.96
AA 16.1% 17.6% 1.07 (0.59–1.97)
AG 46.0% 46.2% 1.11 (0.51–2.44)
GG 37.9% 36.3%
AT1R gene A1166C 0.28
CC 8.0% 11.6% 0.73 (0.41–1.32)
AC 46.0% 34.7% 1.50 (0.55–4.05)
AA 46.0% 53.7%
Bradykinin 2 C58T CC 34.1% 36.8% 0.92 0.89 (0.48–1.63)
TT 18.2% 16.8% 0.91 (0.43–1.96)
CT 47.7% 46.3%
Bradykinin 2 C181T 0.54
CC 72.7% 76.3% 0.83 (0.42–1.62)
TT 1.1% n.a. (empty cells)
CT 26.1% 23.7%
Bradykinin 2 exon1 0.35
-9/-9 38.2% 29.3% 1.08 (0.60–1.94)
-9/+9 43.8% 45.7% 1.49 (0.80–2.77)
+9/+9 18.0% 25.0% 1.52 (0.74–3.12)
CETP I405V 0.02
AA 44.3% 46.8% 0.90 (0.50–1.62)
AG 52.3% 38.3% 4.96 (1.37–17.90)
GG 3.4% 14.9%
CETP TaqIB 0.02
B1B1 24.1% 44.1% 0.40 (0.21–0.77)
B1B2 62.1% 43.0% 0.93 (0.39–2.19)
B2B2 13.8% 12.9%
* Odds ratios (95% Confidence Intervals) for the presence of AF on the electrocardiogram were obtained by logistic regression; the top OR is for 
autosomal dominant model and the bottom for autosomal recessive model.BMC Medical Genetics 2006, 7:39 http://www.biomedcentral.com/1471-2350/7/39
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After identifying the high-risk combinations of factors
using MDR, we applied interaction entropy algorithms to
visualize the observed interactions and to determine
whether they are additive or non-additive (Figure 2).
Entropy analysis showed a small synergistic interaction
between the presence of albuminuria and CETP TaqIB
polymorphism on AF. Next to the independent effects of
both factors, the combination removes an additional
2.52% of the total entropy. The other three significant
interactions found by MDR are mostly additive as illus-
trated by the interaction graph.
Table 3: Summary of Multi-Factor Dimensionality (MDR) results
Model Training Accuracy Testing Accuracy P-value* CVC†
CETP TaqIB – Micro or Macroalbuminuria 0.6761 0.6283 0.04 8/10
CETP TaqIB – C-reactive protein>3 mg/L 0.6650 0.6661 0.002 NA
CETP TaqIB – Renal dysfunction 0.6701 0.6728 0.002 NA
CETP TaqIB – Ischemic heart disease 0.6650 0.6578 0.006 NA
* 1000 fold permutation test
† Cross-validation Consistency
Distribution of high-risk (dark shading) and low-risk (light shading) combinations associated with atrial fibrillation in the four  significant gene-environment models using Multifactor Dimensionality Reduction (MDR) analysis Figure 1
Distribution of high-risk (dark shading) and low-risk (light shading) combinations associated with atrial fibrilla-
tion in the four significant gene-environment models using Multifactor Dimensionality Reduction (MDR) analy-
sis. The percentage of patients with atrial fibrillation (left bar in boxes) and matched control subjects (right bar in boxes) is 
shown for each combination. Boxes were labeled as high-risk (dark-shaded) if the ratio of the percentage of cases to controls 
met or exceeded the threshold of 1.0.BMC Medical Genetics 2006, 7:39 http://www.biomedcentral.com/1471-2350/7/39
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Discussion
This study showed for the first time an association
between the CETP TaqIB polymorphism and AF. Using
the MDR method, we established that the CETP TaqIB
polymorphism in association with other risk factors of AF,
i.e. albuminuria, elevated CRP, renal dysfunction, and
presence of ischemic heart disease could predict AF even
more strongly. Other genetic polymorphisms of genes
encoding bradykinin and elements of the RAS did not cor-
relate with the presence of AF.
The underlying biological mechanism explaining the
association between AF and the CETP TaqIB polymor-
phism remains unclear in this study. A logical explanation
would be that the widely acknowledged association
between CETP gene variations (resulting in lower plasma
CETP) and higher HDL cholesterol levels. [12] may pre-
vent the initiation of (preclinical) atherosclerosis and sub-
sequently the development of AF. This mechanism is very
likely considering the modulating effect of ischemic heart
disease on the association between CETP TaqIB polymor-
phism and AF in the present study.
Data corroborating this have recently been published.
Some studies have linked CETP polymorphisms to cardi-
ovascular disease, hypertension, and even longevity.
[13,31]. Since new-onset AF in about 40% of the cases is
linked to either coronary artery disease, hypertension, or
both. [32], genetic variants impacting the CETP mass may
provide a pathophysiologically rational correlate of AF.
However, ancillary mechanisms such as inflammation,
oxidative stress and use of alcohol cannot be excluded as
the link between CETP and the predisposition to AF.
Decreased CETP activity in the subjects who have the
B2B2 genotype of the CETP TaqIB polymorphism might
prevent oxidation of LDL and decrease inflammation of
the vascular wall through its effect on HDL [11]. In this
study, subjects with AF had lower levels of HDL choles-
terol, but this difference did not reach statistical signifi-
cance due to the small population.
It has recently been recognized that oxidative stress and
inflammation may facilitate the development of AF [33].
The fact that the combination of an elevated CRP and
CETP TaqIB polymorphism was more powerful in predict-
ing AF than either one alone indicate a potential role of
inflammation as underlying mechanism. Another com-
mon pathway might be the presence of insulin resistance,
which has been suggested to contribute to the develop-
ment of AF [34]. Variations in the CETP gene might influ-
ence the different components of insulin resistance [35].
The significant interaction between CETP TaqIB polymor-
phism and renal dysfunction and especially the presence
of albuminuria in predicting AF, pleads for (at least in
part) accessory pathway involving the renin-angiotensin
system. One common denominator could be the altered
expression of liver X receptor, which in turn might modu-
late CETP expression as well as renin expression, although
this is highly speculative. [36,37].
The MDR method indicated four significant two-way
interaction models, but did not specify whether there is a
synergistic relationship. Therefore, we created an interac-
tion entropy graph to visualize and interpret the observed
interactions. This graph showed that the interaction
between albuminuria and CETP TaqIB was (partly) syner-
gistic in the presence of significant main effects. If the
interaction between albuminuria and CETP TaqIB was
purely additive, the total amount of entropy removed
would be 13.0%, but instead the total amount of entropy
removed by the combination of CETP TaqIB and albu-
minuria was 15.5%, indicating a synergistic interaction.
Interaction entropy graph Figure 2
Interaction entropy graph. The interaction models illus-
trated in the interaction graph describe the percent of the 
entropy in case-control status (i.e. presence of atrial fibrilla-
tion) that is explained by each factor or two way interaction. 
Each gene or environmental factor is shown in a box with the 
percent of entropy below the label. Two way interactions 
between factors are depicted as an arrow accompanied by a 
percent of entropy explained by that interaction. Redun-
dancy is depicted as a line between factors accompanied by a 
negative percent of entropy. LVH: Left ventricular hypertro-
phy. IHD: Ischemic heart disease. CRP: C-reactive protein.BMC Medical Genetics 2006, 7:39 http://www.biomedcentral.com/1471-2350/7/39
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On the other hand, an additive interaction was observed
between the CETP TaqIB polymorphism and elevated C-
reactive protein, presence of renal dysfunction or ischemic
heart disease. It is therefore more likely that the found
interactions between the CETP TaqIB polymorphism and
elevated C-reactive protein, presence of renal dysfunction
or ischemic heart disease are not biological meaningful.
The relation between polymorphisms of the renin-angi-
otensin system and AF found by Tsai et al [7]. could not
be replicated in our case-control study. Possibly, our study
was underpowered. It is important to note the difference
in ethnicity between the two samples (Caucasian vs. Tai-
wanese). It is possible that the RAS genes influence sus-
ceptibility to AF differently in the context of different
genetic backgrounds. Moreover, studies of genetic poly-
morphisms of the RAS have been generating conflicting
results, possibly due to small sample size, inadequate
study populations, and unconditional statistics. A con-
tributory role of genetic variants of the ACE, angiotensin,
and AT1R genes in AF is in our opinion still open to
debate.
A limitation of our study is the relatively small sample
size. The CETP I405V polymorphism deviated from HWE
in the control group which could arise due to the small
sample of the population and the results of this CETP pol-
ymorphism needs to be interpreted with caution. On the
other hand, the MDR method, which has been validated
in studies with small samples, confirmed the association
between CETP TaqIB polymorphism and AF detected by
traditional logistic regression analyses. Furthermore, the
Armitage test for trend in proportions which does not
assume HWE, showed a significant trend between the
CETP TaqIB polymorphism and AF. However, the CETP
TaqIB polymorphism is not likely to be functional and is
probably a marker for one or several functional variants
located within the CETP gene or its vicinity. Thus, the
results found in this study need to be confirmed in
another population preferable with a larger size. Until
then, these data are rather hypothesis generating than def-
inite.
Additional studies need also to be done to establish the
underlying mechanisms explaining the association
between CETP TaqIB polymorphisms and AF and to
understand the interactions among CETP TaqIB polymor-
phism and presence of micro- or macroalbuminuria, ele-
vated CRP, renal dysfunction, and ischemic heart disease.
Clinical trials investigating pharmacological inhibitors of
CETP might consider to include AF as exploratory out-
come.
Also, in this population based cohort, no clinical informa-
tion such as echocardiographic features could be obtained
due to the epidemiological nature of the study. In addi-
tion, the type of AF (paroxysmal or persistent) could not
be determined, because one standard 12 lead electrocardi-
ogram was made during two minutes.
Conclusion
In summary, we observed an association between AF and
TaqIB polymorphism of the CETP gene. Using the MDR
method, we showed that the combination of CETP TaqIB
polymorphism and the presence of albuminuria, an ele-
vated CRP, renal dysfunction or ischemic heart disease are
the best models for predicting AF in this nested case-con-
trol study. Further studies are warranted to further eluci-
date this association and to investigate whether a true
biological link exits between CETP and AF or that both are
associated with a common factor such as e.g. atherosclero-
sis, hypertension, inflammation, oxidative stress or alco-
hol intake.
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